SCHEMBL8848435

SCHEMBL8848435

O=C(c1ccc(Cl)nc1)C(F)(F)F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.60
KCNQ3 O43525 5/20 0.50
KCNQ2 O43526 5/20 0.50
KCNE1 P15382 5/20 0.50
KCNQ1 P51787 5/20 0.50
GRM4 Q14833 1/20 0.50
DGAT1 O75907 2/20 0.46
BACE1 P56817 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
CES1 P23141 1/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MDM4 O15151 1/20 0.43
TP53 P04637 1/20 0.43
MDM2 Q00987 1/20 0.43
EGFR P00533 1/20 0.43
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25327524 0.85 NAPRT (0.56) NAPRTKCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL13028710 0.81 NAPRT (0.60) NAPRTKCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL2937504 0.79 NAPRT (0.58) NAPRTKCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL5321257 0.78 CES1 (0.47) KCNQ3KCNQ2HDAC6CES1L3MBTL1
SCHEMBL10575120 0.78 NAPRT (0.67) NAPRTKCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL25177793 0.78 JUN (0.47) NAPRTKCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL8099539 0.78 PLOD2 (0.56) NAPRTKCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL17801 0.77 NAPRT (0.72) NAPRTKCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL29760376 0.77 NAPRT (0.72) NAPRTKCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL7440808 0.77 NAPRT (0.72) NAPRTKCNQ3KCNQ2KCNE1KCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719394-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2026-04-08 EP disclosed
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE ATOMWISE INC (US) 2026-02-19 US disclosed
US-12358904-B2 Inhibitors of TYK2 Atomwise Inc. (US) 2025-07-15 US disclosed
US-20240425484-A1 INHIBITORS OF TYK2 Atomwise Inc. 2024-12-26 US disclosed
US-20240417396-A1 INHIBITORS OF TYK2 Atomwise Inc. 2024-12-19 US disclosed
WO-2024250010-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2024-12-05 WO disclosed
US-20200181134-A1 Antiparasitic Compounds CAMBREX CHARLES CITY, INC. 2020-06-11 US disclosed
EP-2678329-B1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-11-18 EP disclosed
US-8889704-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2014-11-18 US disclosed
US-20140005213-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-01-02 US disclosed
EP-2678329-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS Array Biopharma, Inc. (US) 2014-01-01 EP disclosed
WO-2012154274-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2012-11-15 WO disclosed
EP-0623103-B1 PROCESS FOR PRODUCING TRIFLUOROMETHYL KETONES HOECHST SCHERING AGREVO GMBH (DE) 1997-09-03 EP disclosed
US-5608062-A Process for preparing trifluoromethyl ketones HOECHST SCHERING AGREVO GMBH (DE) 1997-03-04 US disclosed
EP-0623103-A1 PROCESS FOR PRODUCING TRIFLUOROMETHYL KETONES. HOECHST SCHERING AGREVO GMBH (DE) 1994-11-09 EP disclosed
WO-1993014054-A1 PROCESS FOR PRODUCING TRIFLUOROMETHYL KETONES HOECHST SCHERING AGREVO GMBH (DE) 1993-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240417396-A1 INHIBITORS OF TYK2 TYK2, LCK, JAK2 NAPRT 2630/4885KCNQ3 1203/4885KCNQ2 1021/4885
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE TYK2, FRK, DYRK2 NAPRT 4105/4885KCNQ3 2380/4885KCNQ2 2838/4885
US-20140005213-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 NAPRT 3920/4885KCNQ3 634/4885KCNQ2 653/4885
US-12358904-B2 Inhibitors of TYK2 TYK2, LCK, JAK2 NAPRT 2630/4885KCNQ3 1203/4885KCNQ2 1021/4885
US-20200181134-A1 Antiparasitic Compounds ACHE, DDT, NISCH NAPRT 3056/4885KCNQ3 1141/4885KCNQ2 1098/4885
US-20240425484-A1 INHIBITORS OF TYK2 TYK2, LCK, JAK2 NAPRT 2630/4885KCNQ3 1203/4885KCNQ2 1021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.